We study the genetic and epidemiologic determinants of lymphoma and its precursor states, with a focus on persistent lymphocytosis, monoclonal B cell lymphocytosis (MBL), and chronic lymphocytic leukemia (CLL).
Our work integrates genomics, population based data, clinically annotated cohorts, and biospecimen based analyses to improve risk stratification and inform future prevention and care.
We also incorporate electronic medical records from Israeli HMOs, alongside biospecimen and questionnaire data collected in collaboration with HMOs and hospitals across Israel.
• MBL prevalence, progression, and clinical consequences
• Genetic susceptibility and multi ancestry genomics
• Familial CLL and high risk populations
• Immune dysregulation, infections, and cancer outcomes
• Patient centered outcomes and quality of life